Page 4 - Laurus Lab News Today

Brokerage Antique Stock Broking believes that the mid-cap space will continue to offer wealth creating opportunities to investors, citing the ongoing economic recovery. However, it added that there is a need to stay selective due to rich valuations.

Ace investor Madhu Kela says in an economic uptrend, the economy-related stocks are going to do well. He says he has been positive and vocal on the entire real estate and real estate ancillary space

Laurus Labs’ Q4 net at ₹297 crore April 29, 2021 Its total revenue increased 68% at ₹1,412 crore Laurus Labs Ltd’s consolidated net profit more than doubled at ₹297 crore in the fourth quarter ended March 31, 2021 compared to ₹110 crore in the corresponding quarter of the previous fiscal. The total revenue increased 68 per cent at ₹1,412 crore. For the full year, the net profit increased 286 per cent to ₹984 crore on a revenue of ₹4,814 crore which registered 68 per cent inc...

Laurus Labs on Thursday said that Satyanarayana Chava, its Founder Promoter, CEO & ED, sold 52 lakh shares of the company. The shares were sold on Thursday at an average price of ₹368.59, ag

Explore Now Among largecaps, HCL Technology makes sense valuation wise and there are a lot of opportunities in midcaps also, says Quantum Securities. From a valuation standpoint, how does IT stack up and would you be also looking at a lot of the midcap IT names? Neeraj Dewan: We were looking at midcap IT but after the correction in largecap IT, it makes sense to invest more in IT largecaps. The last quarter’s numbers were pretty good and even the deal wins are good. Stocks like TCS, HCL Tec...

The pharmaceutical ingredients maker said that its wholly-owned subsidiary, Laurus Synthesis, incorporated a subsidiary by the name of Laurus Ingredients with effect from 9 January 2021.Laurus Ingredients, a step-down subsidiary of Laurus Labs, will undertake ingredients business and will also set up greenfield projects for new synthesis business. The announcement was made after market hours yesterday, 11 January 2021. Laurus Labs consolidated net profit surged 328.4% to Rs 242.27 crore on a 59...

Shares of pharmaceutical companies were in focus on Monday with Nifty Pharma index hitting a fresh record high of 12,836 on the National Stock Exchange (NSE) in an otherwise subdued market. Cipla, Cadila Healthcare, Lupin, Sun Pharmaceutical Industries and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE. Meanwhile, Marksans Pharma, Suven Pharma, Novartis, Indoco Remedies, Glenmark Pharmaceuticals, Dr. Lal PathLabs, RPG Life Sciences, S...

Explore Now NEW DELHI: Six companies from the BSE500 pack have reported growth in profit margins for back-to-back four quarters. Five of these stocks have climbed up to 356 per cent so far this year, against a 12 per cent rise in the Sensex. They include Laurus Labs, Divi’s Laboratories, Mindtree, Aegis Logistics and Ambuja Cements. The sixth stock, Vakrangee, is up 6 per cent this year. The margin gains for these firms in the last four quarters were in the 5-13 percentage points range. Lauru...